Excellergy

Excellergy is a biotechnology company focused on developing a pioneering portfolio of trifunctional effector cell response inhibitors (ECRIs) to address severe allergic diseases. By utilizing clinically validated Immunoglobulin E (IgE) biology and innovative ECRI pharmacology, Excellergy aims to surpass traditional anti-IgE therapies by directly targeting the source of allergic signaling—IgE bound to effector cells. Headquartered in Palo Alto, California, the company is committed to advancing the standard of care in allergy treatment and improving patient quality of life.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―

Total Amount Raised$70M

Total Funding Rounds1

Latest Funding Amount$70M

Latest Funding RoundSeries A

Post-Money Valuation―

Funding Round

Oct 13, 2025

Series A

$70.00M

―

Investors

Samsara BioCapital

Series A

Red Tree Venture Capital

Series A

Decheng Capital

Series A

Excellergy

Leadership & Board

Latest Estimated Valuation

Funding Round

Investors

Related News and Analysis

Novartis to Acquire Excellergy in Allergy Drug Deal Worth Up to $2 Billion

Excellergy Advances First-in-Class Allergy Drug Exl-111 Into Phase 1, Backed by Strong Preclinical Data

Remodel Health Posts Record 2025 Growth, Scales ICHRA Platform and Leadership for 2026

Bitsight Tops Forrester Cybersecurity Risk Ratings Evaluation With Best Current Offering

Plenful Launches MFP Intelligence Platform to Protect Health System Drug Refunds

Brightspeed Launches EasyMove to Lock In Customer Loyalty During Relocations

Numa Triples Revenue, Tops 1,300 Dealerships and Buys Ficus to Push Deeper Into AI-Powered Sales

Censys Launches Real-Time Risk Scoring to Deepen Its Role in Modern SOC Operations

Guideline Launches Market Monitor to Turn Verified Ad Spend Data into Weekly Intelligence

Talkiatry Launches Embedded EMR Tool to Streamline Psychiatric Referrals for Health Systems